Genentech, Inc.

Cytomx Therapeutics, Inc.

Genetech, Inc.

Luc Roland Desnoyers

William I Wood

Austin L Gurney

Audrey Goddard

Paul J Godowski

Colin K Watanabe

Kevin P Baker

Ellen Filvaroff

Daniel Tumas

Timothy Andrew Stewart

Victoria Smith

James Pan

Mary E Gerritsen

Wei-Qiang Gao

Zemin Zhang

Napoleone Ferrara

J Christopher Grimaldi

Dan L Eaton

Margaret Ann Roy

Sherman Fong

David Botstein

P Mickey Williams

Kenneth J Hillan

Nicholas F Paoni

Avi J Ashkenazi

Hanspeter Gerber

Ivar J Kljavin

Henry Bernard Lowman

Maureen H Beresini

Steven W Sherwood

Laura Deforge

Jennie Powell Mather

Jian Chen

Jason Gary Sagert

Shouchun Liu

Dorothy French

James William West

Shweta Singh

Annie Yang Weaver

Mary A Napier

Jonathan Alexander Terrett

Olga Vasiljeva

Jean-Philippe F Stephan

Elizabeth-Edna Mary Menendez

Tony Liang

Mark S Dennis

Sophia S Kuo

Wei-Giang Gao

Andrei William Konradi

David L Shelton

Kimberly Ann Tipton

Diane Pennica

Jenni P Mather

Amy Grace DuPage

The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.

Compositions and methods for conjugating activatable antibodies

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Activatable antibodies that bind epidermal growth factor receptor and methods thereof

The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain ('ICD') of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.

Anti-CD166 antibodies and uses thereof

Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.

Antibodies that bind activatable antibodies and methods of use thereof

Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

Growing community of inventors

San Francisco, CA, United States of America

Luc Roland Desnoyers